gpr85 Antibody

What is GPR85 and why is it significant for neuroscience research?

GPR85/SREB2 belongs to the super-conserved receptor expressed in brain (SREB) family and is the most conserved G-protein-coupled receptor in vertebrate evolution. It functions as an orphan receptor (with unknown ligand) that regulates neural and synaptic plasticity . GPR85 is robustly expressed in the hippocampal formation, especially in the dentate gyrus, a structure with established involvement in psychiatric disorders and cognition . Its high evolutionary conservation suggests critical biological functions, making it an important target for neuroscience research.

What types of GPR85 antibodies are currently available for research?

Current research can utilize multiple types of GPR85 antibodies:

• Monoclonal antibodies: Including Mouse Anti-Human GPR85 Monoclonal Antibody (e.g., Clone # 1042202)

• Polyclonal antibodies: Primarily rabbit-derived polyclonal antibodies targeting different epitopes

• Domain-specific antibodies: Antibodies targeting specific regions such as extracellular domain , C-terminal , and N-terminal regions

These are available in both conjugated and unconjugated forms with reactivity against multiple species including human, mouse, rat, zebrafish, and others .

How do I select the appropriate GPR85 antibody for my experimental design?

Selection should be based on several critical factors:

For detecting GPR85 in neural tissues, antibodies validated for IHC-P are commonly used with successful detection in human brain tissue samples .

What are the optimal conditions for immunostaining GPR85 in neural tissues?

Based on published research protocols:

For immunohistochemistry in formalin-fixed, paraffin-embedded human brain tissue:

• Antibody concentration: 5.5-17 μg/ml depending on the antibody used

• Incubation time: Typically 3 hours at room temperature

• Secondary antibody: NorthernLights™ 557-conjugated Anti-Rabbit IgG or similar fluorescent conjugates

• Counterstaining: DAPI for nuclear visualization

For cellular localization studies, GPR85 has been successfully detected in immersion-fixed U-87 MG human glioblastoma/astrocytoma cell line with specific staining localized to cytoplasm .

How can I validate the specificity of a GPR85 antibody in my experimental system?

Multiple validation approaches should be employed:

• Positive and negative control cell lines: U-87 MG human glioblastoma/astrocytoma cell line (positive control) versus A549 human lung carcinoma cell line (negative control)

• Genetic validation approaches:

  • Use of GPR85 knockout models as negative controls

  • Overexpression systems with tagged GPR85 for co-localization studies

• Peptide competition assays: Pre-incubation of the antibody with immunizing peptide

• Cross-validation with different antibodies targeting distinct epitopes of GPR85

• Transcript correlation: Validation by comparing protein detection with mRNA expression patterns

What are the recommended storage and handling conditions for GPR85 antibodies?

For optimal antibody performance and longevity:

• Storage temperature:

  • Long-term (12 months): -20 to -70°C as supplied

  • Medium-term (1 month): 2 to 8°C under sterile conditions after reconstitution

  • Short-term (6 months): -20 to -70°C under sterile conditions after reconstitution

• Critical handling guidelines:

  • Use a manual defrost freezer and avoid repeated freeze-thaw cycles

  • Reconstitute according to manufacturer's instructions

  • Maintain sterile conditions after reconstitution

  • Aliquot to minimize freeze-thaw cycles

How can GPR85 antibodies be used to investigate synaptic localization and function?

Recent research has revealed GPR85's synaptic localization and functional importance:

• Synaptic enrichment studies:

  • GPR85 is enriched at both excitatory and inhibitory chemical synapses in developing and adult brain

  • The receptor localizes to both pre- and postsynaptic sites of ribbon synapses in the retina

  • Electron microscopy with immunogold labeling confirms plasma membrane localization in vivo

• Experimental approaches:

  • Co-immunoprecipitation to confirm association with postsynaptic density protein (PSD)-95

  • Dual immunostaining with pre/postsynaptic markers (e.g., Ribeye-a)

  • Pull-down assays to identify proteins that associate with the C-terminal sequence of GPR85

• Functional assays:

  • Electrophysiological analysis of neurons in GPR85 knockout models shows increased firing rates and higher membrane resistance, suggesting involvement in regulating neuronal excitability

  • Light-triggered startle response assays in zebrafish reveal behavioral consequences of GPR85 deficiency

What is known about GPR85's role in neuropsychiatric disorders, and how can antibodies help investigate this?

GPR85 has been implicated in several neuropsychiatric conditions:

• Schizophrenia association:

  • Human genetic studies revealed that schizophrenia patients with risk haplotypes of SREB2 showed reduced hippocampal volume

  • SREB2 transgenic mice exhibit schizophrenia-like phenotypes including reduced brain size, sensory gating deficits, social interaction deficits, and cognitive impairments

• Autism Spectrum Disorder (ASD) connection:

  • GPR85 associates with PSD-95 linked with neuroligin, a protein implicated in ASD

  • Mutations in GPR85 have been identified in patients with ASD

• Research applications of antibodies:

  • Comparative immunohistochemistry between control and patient-derived tissues

  • Quantitative analysis of GPR85 expression in affected brain regions

  • Investigation of mutant GPR85 cellular localization and effects on neuronal morphology

  • Co-localization studies with other psychiatric risk factor proteins

How can GPR85 antibodies be employed in studying adult neurogenesis?

SREB2/GPR85 has been identified as a negative regulator of adult neurogenesis:

• Experimental approaches:

  • Combined bromodeoxyuridine (BrdU) incorporation and GPR85 immunohistochemistry to quantitatively assay adult neurogenesis

  • Immunostaining for DCX (doublecortin) and calretinin as markers of newborn neurons

  • Analysis of newborn neuron dendritic morphology in SREB2 transgenic and knockout mice

• Quantification methods:

  • Confocal microscopy with Z-stack imaging (0.5 μm optical intervals)

  • Double-channel histogram intensity analysis for co-localization confirmation

  • Real-time cell counting using BrdU/NeuN-positive cells

How do I address potential cross-reactivity issues with GPR85 antibodies?

Cross-reactivity is a common challenge with GPCR antibodies due to structural similarities:

• Systematic validation approaches:

  • Use multiple antibodies targeting different epitopes and compare results

  • Include appropriate negative controls (tissues/cells lacking GPR85 expression)

  • Validate using GPR85 knockout or knockdown models

• Addressing discrepancies:

  • Consider post-translational modifications affecting epitope recognition

  • Evaluate antibody specificity using western blot analysis to confirm correct molecular weight

  • Optimize antibody concentration using titration experiments

  • Adjust blocking conditions to reduce non-specific binding

How can I reconcile conflicting data from different GPR85 antibodies?

When facing inconsistent results:

• Epitope consideration:

  • Different antibodies target distinct regions (extracellular domain , C-terminal ) which may have differential accessibility depending on experimental conditions

  • Some epitopes may be masked by protein interactions or conformational changes

• Technical approaches:

  • Compare subcellular localization patterns between antibodies

  • Validate with orthogonal methods (e.g., tagged GPR85 overexpression)

  • Consider native versus denatured conditions affecting epitope exposure

  • Evaluate fixation effects on epitope preservation

• Data integration strategies:

  • Weight evidence based on validation quality

  • Consider combining data from multiple antibodies for comprehensive analysis

  • Correlate with functional assays to resolve conflicting structural observations

What are the methodological considerations when investigating GPR85 mutations?

For mutation studies such as those identifying M152T and V221L variants in ASD patients :

• Experimental design:

  • Site-directed mutagenesis to generate GPR85 mutants using appropriate primers

  • Expression vector selection for cellular assays

  • Antibody selection ensuring epitope preservation in mutant proteins

• Analysis approaches:

  • Immunostaining to examine intracellular localization of mutated GPR85

  • Evaluation of morphological changes in cells and neurons expressing mutant GPR85

  • Quantification of apoptotic morphology and stress markers (CHOP, P-eIF2, caspase-3)

• Statistical considerations:

  • Appropriate sample sizes (e.g., 200 cells per condition)

  • Experimental replication (at least three independent experiments)

  • Statistical analysis using Student's t-tests with significance thresholds (p < 0.05 or p < 0.01)

How can GPR85 antibodies contribute to understanding neurodevelopmental processes?

Recent studies highlight GPR85's role in neural development:

• Developmental expression patterns:

  • Temporal and spatial mapping of GPR85 expression during brain development

  • Correlation with critical developmental windows

  • Analysis of GPR85 expression in neural progenitor populations

• Functional implications:

  • The rat counterpart of SREB2 is involved in cerebral cortex development

  • GPR85 influences cerebellar granule cell electrical properties

  • Potential role in regulating neuronal excitability during development

• Cutting-edge approaches:

  • Single-cell transcriptomic analysis combined with immunostaining

  • Temporal GPR85 knockout models to assess stage-specific requirements

  • Advanced imaging techniques to track GPR85-expressing cells during development